Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines
Pancreatic ductal adenocarcinoma (PDAC) correlates with high mortality and is about to become one of the major reasons for cancer-related mortality in the next decades. One reason for that high mortality is the limited availability of effective chemotherapy as well as the intrinsic or acquired resis...
Main Authors: | Lukas M. Braun, Simon Lagies, Jessica Guenzle, Stefan Fichtner-Feigl, Uwe A. Wittel, Bernd Kammerer |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/5/1251 |
Similar Items
-
Microbiome in pancreatic cancer – What is new in 2024?
by: E. Hohmann, et al.
Published: (2024-10-01) -
Risk prediction of pancreatic cancer using AI analysis of pancreatic subregions in computed tomography images
by: Sehrish Javed, et al.
Published: (2022-11-01) -
Roles of microbiota in pancreatic cancer development and treatment
by: Mariana Santos Cruz, et al.
Published: (2024-12-01) -
Oral mycobiota and pancreatic ductal adenocarcinoma
by: Ailin Wei, et al.
Published: (2022-12-01) -
Ferroptosis: New Strategies and Ideas for the Treatment of Pancreatic Ductal Adenocarcinoma
by: Chengru Yang, et al.
Published: (2024-01-01)